{"groups":[{"description":"Fludarabine 25 mg/m\\^2 intravenous (IV) daily for 5 days prior to allogeneic peripheral blood progenitor cell (PBPC) , Melphalan 70 mg/m\\^2 IV daily for 2 days prior to IV Allogeneic Transplant following Fludarabine \\& Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 \\& -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.","id":"FG000","title":"Fludarabine + Melphalan With PBPC"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"15"}],"type":"Disease Progression/Relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"22"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Recruitment Period: September 26, 2003 to November 05, 2012. All recruitment done at The University of Texas MD Anderson Cancer Center."}